COG

COG ChildrensOncology Group (click for all protocols, scroll to the appropriate protocol)

A5971-A Randomized Phase III Study For The Treatment Of Newly Diagnosed Disseminated Lymphoblastic Lymphoma
Status: Active Enrolling
PI: Joseph Neglia MD
Contact Number: Amanda Galster 612-625-4443

ACNS0121 A Phase II Trial Of Conformal RT For Pediatric Patients With Localized Ependymoma, Chemotherapy Prior To 2^nd Surgery For Incompletely Resected Ependymoma And Observations For Completely Resected, Differentiated , Supratentorial Ependymoma
Status: Active Enrolling
PI: Joseph Neglia MD
Contact Number: Amanda Galster 612-625-4443

AHOD0031 A Phase III Study Of Dose –Intensive, Response Based Chemotherapy And Radiation Therapy For Children and Adolescents With Newly Diagnosed Intermediate Risk Hodgkin’s Disease
Status: Active Enrolling
PI: Joseph Neglia MD
Contact Number: Amanda Galster 612-625-4443

AHOD0431
A Phase III Study for the Treatment of Children and Adolescents With Newly Diagnosed Low Risk Hodgkin Disease
Status: Active enrolling
PI: Joe Neglia, MD
Data Collection: Amanda Galster, 612 625-4443

AALL0331
Standard Risk B-precursor Acute Lymphoblastic Leukemia
Status: Active enrolling
PI: Joe Neglia, MD
Data Collection: Amanda Galster, 612 625-4443

ACNS0122
A Phase II Study to Assess the Ability of Neoadjuvant Chemotherapy +/- Second Look Surgery to Eliminate All Measurable Disease Prior to Radiotherapy for NGGCT
Status: Active enrolling
PI: Joe Neglia, MD
Data Collection: Amanda Galster, 612 625-4443

ANHL01P1
A Pilot Study to Determine the Toxicity of the Addition of Rituximab to the Induction and Consolidation Phases and the Addition of Rasburicase to the Reduction Phase in Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated with LMB/FAB Therapy
Status: Active enrolling
PI: Joe Neglia, MD
Data Collection: Amanda Galster, 612 625-4443

ARST0431
Intensive Multi-Agent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide (IE) and Vincristine/Doxorubicin/Cyclophosphamide (VDC) for Patients with High-Risk Rhabdomyosarcoma
Status: Active enrolling
PI: Joe Neglia,
Data Collection: Amanda Galster, 612 625-4443

ACNS0331
A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial
Status: Active enrolling
PI: Joe Neglia, MD
Data Collection: Amanda Galster, 612 625-4443

AOST0331
A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-operative Chemotherapy (IND# 12697)
Status: Active enrolling
PI: Joe Neglia, MD
Data Collection: Amanda Galster, 612 625-4443

ACNS0224
A Phase I/II Study of Topotecan With G-CSF and Radiation Therapy In the Children with Malignant Intrinsic Pontine Brainstem Gliomas of Childhood
Status: Active enrolling
PI: Joe Neglia, MD
Data Collection: Amanda Galster, 612 625-4443

AAML0531
A phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined with Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults
Status: Active enrolling
PI: Joe Neglia, MD
Data Collection: Amanda Galster, 612 625-4443

AEWS0331
European Ewing Tumor Working Initiative of National Groups Ewing Tumour Studies 1999 (EURO-E.W.I.N.G. 99) COG participation in AEWS03 is LIMITED TO PATINETS WITH ISOLATED PULMONARY METASTSES. PATIENTS WITH LOCALIZED TUMORS OR ANY NON-PULMONARY METASTASES ARE NOT ELIGIBLE.
Status: Active enrolling
PI: Joe Neglia, MD
Data Collection: Amanda Galster, 612 625-4443